Back to Agenda
[Session 2]Clinical / ECG
Session Chair(s)
Atsushi Sugiyama, MD, PhD
Professor and Chairman, Department of Pharmacology
Toho University Faculty of Medicine, Japan
![Kyosuke Takeshita, MD, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Kyosuke Takeshita, MD, PhD
Department of Clinical Laboratory Medicine
Saitama Medical Center, Saitama Medical University, Japan
Speaker(s)
Replacing the Thorough QT study with Concentration-QTc analysis applied to First-in-Human studies – recent trends and experience from interactions with regulators
Börje C. Darpö, MD, PhD
Clario, Sweden
Chief Scientific Officer, Cardiac Safety
Current status and future perspective of clinical proarrhythmic risk assessment from a regulatory point of view
Kaori Shinagawa, MD, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Senior Scientist for Clinical Medicine, Office of New Drug II
Reasons why it is difficult to evaluate cardiac safety for antidiabetic drugs - Findings obtained in a type 1 diabetes study examining the effects of diet on normal and insulin-deficient subjects
Jorg Taubel, MD, FFPM
Richmond Pharmacology, United Kingdom
Chief Executive Officer
Boaz Mendzelevski, MD
Cardiac Safety Consultants Ltd., United Kingdom
Consultant Cardiologist
Have an account?